Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Top Cited Papers
- 1 February 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (3), 843-850
- https://doi.org/10.1200/jco.2001.19.3.843
Abstract
PURPOSE: We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS...This publication has 12 references indexed in Scilit:
- Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesisBlood, 2000
- NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODELJournal of Urology, 1999
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitisJournal of Allergy and Clinical Immunology, 1997
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limbThe Lancet, 1996
- Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of strokeNeuroradiology, 1996
- Consequences of angiogenesis for tumor progression, metastasis and cancer therapyAnti-Cancer Drugs, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of ProteinsEndocrine Reviews, 1992
- The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal AntibodiesGrowth Factors, 1992